Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

Bioceltech Therapeutics

Status and phase

Enrolling

Phase 1

Conditions

T Cell Lymphoblastic Lymphoma

Treatments

Biological: BT-007 CD7 CAR-T cells

Study type

Interventional

Funder types

Industry

Identifiers

NCT05554575

BT-LBL-007-v2

Details and patient eligibility

About

This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of T cells expressing CD7 chimeric antigen receptors (referred to as "BT-007 CAR-T cells") in patients with relapsed or refractory acute T cell lymphoblastic lymphoma (R/R T-LBL).

Full description

Primary objective:

To investigate the safety and efficacy of CD7 CAR-T cells in the treatment of patients with relapsed or refractory acute T cell lymphoblastic lymphoma (R/R T-LBL).

Secondary objective:

To assess the patient's quality of life after receiving the treatment.

Enrollment

15 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with CD7 positive T-cell lymphoma confirmed by histology;
Relapsed refractory patients who received at least one line of systemic chemotherapy in the past;
At least one measurable target lesion;
Age: 18-70 years old (including 18 and 70 years old);
The expected survival period is more than 3 months;
Eastern Cooperative Oncology Group (ECOG) score 0-1;
Important organ functions met: left ventricular ejection fraction≥50% according to cardiac ultrasound; Serum Cr≤1.25 times the upper limit of normal range (ULN) or endogenous creatinine clearance≥45mL/min (Cockcroft Gault formula); ALT and AST≤3 times ULN, TBIL≤1.5 times ULN;
Blood routine: hemoglobin (Hgb)≥80g/L, neutrophil count (ANC)≥1×10^9/L, platelet PLT≥50×10^9/L；
Coagulation function: International standardized ratio (INR)≤1.5 times ULN; Activated partial thromboplastin time (APTT)≤1.5 times ULN (unless the subject is receiving anticoagulant treatment, and prothrombin time (PT)/INR and APTT are within the expected range of anticoagulant treatment at the time of screening);
The pregnancy test of women of childbearing age must be negative; Both male and female patients need to agree to use effective contraceptive measures during the treatment period and within the following 1 year;
Participate in this test voluntarily and sign the informed consent.

Exclusion criteria

Used immunosuppressive agents or therapeutic doses of corticosteroids (defined as prednisone>20mg or equivalent dose) within one week before blood collection, or used drugs that stimulate bone marrow hematopoiesis, such as Human Granulocyte Colony Stimulating Factor (G-CSF); But physiological substitution, topical or inhaled steroids are permitted;
Uncontrolled systemic active fungi, bacteria, viruses or other infections;
Active hepatitis B (HBV DNA>500IU/mL), hepatitis C (HCV RNA positive) or human immunodeficiency virus (HIV) antibody positive;
Central nervous system invasion, or central nervous system disease history, such as epilepsy, cerebrovascular disease, etc;
Pregnant or lactating women, or patients do not agree to use effective contraceptives during treatment and within the following 1 year;
Receiving allogeneic hematopoietic stem cell transplantation or organ transplantation;
Previous history of other malignant tumors. Patients with cured skin basal or squamous cell carcinoma and cervical carcinoma in situ at any time before the study were not included; Patients with other tumors not listed above, but which have been cured by surgery but not by other further treatment measures, and disease-free survival≥5 years, can be included in the study;
Patients with primary immunodeficiency or autoimmune diseases, but asymptomatic hypothyroidism, or well controlled type I diabetes can participate in this study;
Patients who participated in other clinical trials within 4 weeks before blood collection;
The investigator considers that there are other factors that are not suitable for inclusion or affect the subjects to participate in or complete the study.